Northland Securities Initiates Coverage on Check-Cap (NASDAQ:MBAI)

Stock analysts at Northland Securities initiated coverage on shares of Check-Cap (NASDAQ:MBAI – Get Free Report) in a note issued to investors on Monday, Briefing.com reports. The firm set an “outperform” rating and a $10.00 price target on the stock. Northland Securities’ price target points to a potential upside of 136.13% from the company’s previous close.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.00.

Get Check-Cap alerts:

Get Our Latest Stock Analysis on Check-Cap

Check-Cap Trading Down 7.7%

MBAI stock traded down $0.35 during midday trading on Monday, hitting $4.24. The stock had a trading volume of 8,672 shares, compared to its average volume of 131,836. Check-Cap has a 52 week low of $3.88 and a 52 week high of $27.44. The stock has a 50-day simple moving average of $7.23 and a 200 day simple moving average of $9.55. The firm has a market capitalization of $5.84 million, a price-to-earnings ratio of -0.30 and a beta of 0.67.

Check-Cap Company Profile

(Get Free Report)

Check-Cap Ltd. was an Israel-based medical diagnostics company focused on developing noninvasive technologies for colorectal cancer screening. Its lead product, C-Scan, was an ingestible, capsule-based imaging system designed to examine the colon for polyps and other abnormalities without requiring the extensive bowel preparation typically associated with conventional colonoscopy.

The C-Scan system was intended to combine a disposable capsule with an external tracking and data-collection system, allowing physicians to review images of the gastrointestinal tract after the capsule passed through the body.

Further Reading

• Five stocks we like better than Check-Cap
• 3 Dividend Stocks Investors May Be Missing in 2026
• 3 Healthcare Stocks Showing Why the Sector Still Has Momentum
• Akamai’s Anthropic Deal Puts $5.5 Billion Behind Its Edge AI Pivot
• 3 Stocks Under the Microscope After Large Insider Sales

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.